SAMN03290945
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.500
- E2F_TARGETS+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- MYC_TARGETS_V1+0.400
- G2M_CHECKPOINT+0.300
- ANGIOGENESIS+0.200
- PANCREAS_BETA_CELLS+0.200
- SPERMATOGENESIS+0.200
- MTORC1_SIGNALING+0.100
- PI3K_AKT_MTOR_SIGNALING+0.100
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.300
- IL6_JAK_STAT3_SIGNALING-0.300
- ADIPOGENESIS-0.200
- ALLOGRAFT_REJECTION-0.200
- APICAL_SURFACE-0.200
- BILE_ACID_METABOLISM-0.200
- COAGULATION-0.200
- COMPLEMENT-0.200
- ESTROGEN_RESPONSE_EARLY-0.200
- ESTROGEN_RESPONSE_LATE-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_VT6C6N6K | medulloblastoma | — | 0.813 |
| 2 | MNG592 | — | — | 0.801 |
| 3 | AUR-AG0M-TTM1-A-2-1-R-A743-41 | — | A | 0.788 |
| 4 | BS_1AYRM596 | medulloblastoma | — | 0.785 |
| 5 | 32a88c36-6b9a-483f-ad00-bf899ae279ba | — | — | 0.785 |
| 6 | 0edf46a2-3dfb-4bae-b642-281e05975bd1 | — | — | 0.780 |
| 7 | SRR11296878 | — | — | 0.776 |
| 8 | TCGA-91-6831-01A-11R-1858-07 | — | cohortA3 | 0.775 |
| 9 | SRR15069603 | — | — | 0.774 |
| 10 | BS_AHEFXG7W | medulloblastoma | — | 0.773 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |